Award
National Institute of Neurological Disorders and Stroke 5U01NS132345-03
Soluble Epoxide Hydrolase Inhibitor GSK2256294 for Acute Ischemic Stroke
Recipient
Oregon Health & Science University, Portland, OR, United States
Award Amount
$311,850.00
Ceiling
$311,850.00
Awarded
February 18, 2025
Identifier
5U01NS132345-03
This award funds research to evaluate the efficacy of the sEH inhibitor GSK2256294 in preclinical stroke models to support clinical trial development for acute ischemic stroke.
Description
The project aims to test the efficacy of GSK2256294, an FDA-approved soluble epoxide hydrolase (sEH) inhibitor, in reducing brain injury after stroke. The study will utilize the transient MCAO model in young adult and aged mice with type 2 diabetes, within the NINDS Stroke Preclinical Assessment Network (SPAN). The goal is to support the rapid advancement of GSK2256294 into clinical trials for acute ischemic stroke (AIS), leveraging its established safety profile.